Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Bekaii-Saab on TAS-102 and Regorafenib in mCRC

Tanios Bekaii-Saab, MD
Published: Thursday, Sep 13, 2018



Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the use of TAS-102 (Lonsurf) and regorafenib (Stivarga) in patients with metastatic colorectal cancer (mCRC).

Patients with refractory mCRC go through first- and second-line therapies, and sometimes third-line therapy. The question becomes what to do for patients who progress beyond second-line therapy. In the past, physicians had very few options, if any, for these patients. Now physicians have 2 oral options with regorafenib and TAS-102, says Bekaii-Saab.

These agents are different from each other, though they follow similar pathways. Regorafenib is a multikinase inhibitor, whereas TAS-102 is a more traditional cytotoxic agent that belongs to the family of fluoropyrimidines, explains Bekaii-Saab. It is not 5-fluorouracil or capecitabine, but it belongs to the same family, and can work when those 2 agents fail, states Bekaii-Saab.

Data on these agents come from separate studies––RECOURSE and CORRECT––that have never been compared head-to-head. What physicians know about their activity comes primarily from their comparison to best supportive care.


Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the use of TAS-102 (Lonsurf) and regorafenib (Stivarga) in patients with metastatic colorectal cancer (mCRC).

Patients with refractory mCRC go through first- and second-line therapies, and sometimes third-line therapy. The question becomes what to do for patients who progress beyond second-line therapy. In the past, physicians had very few options, if any, for these patients. Now physicians have 2 oral options with regorafenib and TAS-102, says Bekaii-Saab.

These agents are different from each other, though they follow similar pathways. Regorafenib is a multikinase inhibitor, whereas TAS-102 is a more traditional cytotoxic agent that belongs to the family of fluoropyrimidines, explains Bekaii-Saab. It is not 5-fluorouracil or capecitabine, but it belongs to the same family, and can work when those 2 agents fail, states Bekaii-Saab.

Data on these agents come from separate studies––RECOURSE and CORRECT––that have never been compared head-to-head. What physicians know about their activity comes primarily from their comparison to best supportive care.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x